Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 65 | 2023 | 697 | 6.040 |
Why?
|
| Lung | 17 | 2023 | 952 | 1.290 |
Why?
|
| Respiratory Function Tests | 16 | 2021 | 188 | 1.060 |
Why?
|
| Pulmonary Emphysema | 10 | 2018 | 107 | 0.910 |
Why?
|
| Asthma | 6 | 2023 | 440 | 0.830 |
Why?
|
| Smoking | 16 | 2018 | 864 | 0.820 |
Why?
|
| Exercise Tolerance | 13 | 2016 | 79 | 0.820 |
Why?
|
| Biomarkers | 13 | 2020 | 1393 | 0.790 |
Why?
|
| Exercise Test | 10 | 2015 | 251 | 0.780 |
Why?
|
| Forced Expiratory Volume | 16 | 2020 | 202 | 0.690 |
Why?
|
| Aged | 54 | 2023 | 14333 | 0.650 |
Why?
|
| Quality of Life | 12 | 2023 | 1223 | 0.640 |
Why?
|
| Spirometry | 10 | 2022 | 111 | 0.630 |
Why?
|
| Metabolomics | 1 | 2019 | 53 | 0.630 |
Why?
|
| Severity of Illness Index | 15 | 2018 | 1543 | 0.610 |
Why?
|
| Energy Metabolism | 1 | 2019 | 379 | 0.520 |
Why?
|
| Middle Aged | 48 | 2021 | 17480 | 0.510 |
Why?
|
| Cytokines | 2 | 2012 | 934 | 0.490 |
Why?
|
| Male | 60 | 2021 | 29717 | 0.490 |
Why?
|
| Female | 61 | 2021 | 32709 | 0.470 |
Why?
|
| Cohort Studies | 17 | 2021 | 2560 | 0.460 |
Why?
|
| Walking | 8 | 2015 | 238 | 0.460 |
Why?
|
| Hospitalization | 9 | 2023 | 1356 | 0.450 |
Why?
|
| Humans | 78 | 2023 | 63152 | 0.450 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2021 | 17 | 0.420 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2012 | 60 | 0.400 |
Why?
|
| Lung Diseases, Obstructive | 2 | 2014 | 34 | 0.390 |
Why?
|
| Prospective Studies | 16 | 2019 | 3270 | 0.370 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 212 | 0.360 |
Why?
|
| Exercise Therapy | 1 | 2012 | 104 | 0.360 |
Why?
|
| Medicare | 5 | 2023 | 610 | 0.350 |
Why?
|
| Genome-Wide Association Study | 3 | 2018 | 359 | 0.350 |
Why?
|
| Carbon Monoxide | 3 | 2021 | 62 | 0.320 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 663 | 0.320 |
Why?
|
| ADAM Proteins | 2 | 2020 | 32 | 0.310 |
Why?
|
| Disease Progression | 11 | 2019 | 1166 | 0.310 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 718 | 0.300 |
Why?
|
| Respiratory Therapy | 2 | 2018 | 12 | 0.290 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2018 | 36 | 0.290 |
Why?
|
| Body Mass Index | 10 | 2018 | 863 | 0.290 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2023 | 143 | 0.260 |
Why?
|
| Comorbidity | 8 | 2022 | 1118 | 0.260 |
Why?
|
| Hand Strength | 3 | 2015 | 34 | 0.260 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 1082 | 0.260 |
Why?
|
| Interleukin-6 | 4 | 2013 | 320 | 0.260 |
Why?
|
| Exome | 2 | 2016 | 77 | 0.250 |
Why?
|
| Adult | 23 | 2023 | 16736 | 0.240 |
Why?
|
| Pneumonia | 2 | 2021 | 289 | 0.240 |
Why?
|
| Epithelial Cells | 2 | 2020 | 389 | 0.230 |
Why?
|
| Chemokines, CC | 3 | 2013 | 13 | 0.220 |
Why?
|
| Smokers | 3 | 2021 | 119 | 0.220 |
Why?
|
| Proteomics | 1 | 2006 | 284 | 0.220 |
Why?
|
| Uteroglobin | 2 | 2015 | 7 | 0.220 |
Why?
|
| Oxygen Consumption | 3 | 2011 | 209 | 0.210 |
Why?
|
| Vascular Calcification | 2 | 2021 | 25 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2020 | 894 | 0.210 |
Why?
|
| Early Detection of Cancer | 3 | 2023 | 315 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2021 | 1606 | 0.200 |
Why?
|
| Survival Rate | 4 | 2019 | 846 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 755 | 0.200 |
Why?
|
| Patient Preference | 1 | 2023 | 84 | 0.200 |
Why?
|
| Risk Assessment | 5 | 2021 | 2066 | 0.190 |
Why?
|
| Beclomethasone | 1 | 2022 | 1 | 0.190 |
Why?
|
| Macrophages, Alveolar | 2 | 2020 | 64 | 0.190 |
Why?
|
| Prognosis | 9 | 2015 | 1741 | 0.190 |
Why?
|
| Vital Capacity | 7 | 2020 | 115 | 0.190 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2022 | 34 | 0.180 |
Why?
|
| Interleukin-8 | 3 | 2012 | 88 | 0.180 |
Why?
|
| Pneumonectomy | 3 | 2015 | 109 | 0.180 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1121 | 0.180 |
Why?
|
| Patient Readmission | 2 | 2023 | 430 | 0.170 |
Why?
|
| Risk Factors | 11 | 2022 | 5331 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2022 | 188 | 0.170 |
Why?
|
| Follow-Up Studies | 10 | 2017 | 2451 | 0.170 |
Why?
|
| Bronchi | 1 | 2020 | 77 | 0.160 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 165 | 0.160 |
Why?
|
| Health Status | 3 | 2015 | 435 | 0.160 |
Why?
|
| United States | 10 | 2023 | 7827 | 0.160 |
Why?
|
| Survival Analysis | 6 | 2020 | 579 | 0.150 |
Why?
|
| Heart Failure | 1 | 2006 | 912 | 0.150 |
Why?
|
| Telemedicine | 1 | 2023 | 323 | 0.150 |
Why?
|
| Pulmonologists | 1 | 2018 | 5 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 5429 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2023 | 6595 | 0.140 |
Why?
|
| Eosinophilia | 1 | 2017 | 32 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 310 | 0.140 |
Why?
|
| Endothelium | 1 | 2017 | 21 | 0.140 |
Why?
|
| Inflammation | 2 | 2015 | 1144 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2018 | 347 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 613 | 0.130 |
Why?
|
| Dyspnea | 4 | 2013 | 123 | 0.130 |
Why?
|
| Interleukin-27 | 1 | 2016 | 6 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2017 | 115 | 0.130 |
Why?
|
| Prevalence | 5 | 2022 | 1375 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2018 | 292 | 0.120 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 9 | 0.120 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 55 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 356 | 0.120 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2006 | 86 | 0.120 |
Why?
|
| Muscle Weakness | 1 | 2015 | 33 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 232 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 674 | 0.120 |
Why?
|
| Interleukin-16 | 2 | 2012 | 25 | 0.120 |
Why?
|
| Chemokine CCL2 | 2 | 2012 | 57 | 0.120 |
Why?
|
| Spain | 4 | 2018 | 33 | 0.120 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2015 | 4 | 0.120 |
Why?
|
| Information Services | 1 | 2015 | 35 | 0.120 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2016 | 69 | 0.120 |
Why?
|
| Smoke | 1 | 2015 | 24 | 0.120 |
Why?
|
| Oxygen | 1 | 2016 | 315 | 0.110 |
Why?
|
| Kidney | 1 | 2017 | 444 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 432 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 101 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 784 | 0.110 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2014 | 3 | 0.110 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 2673 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 477 | 0.110 |
Why?
|
| Busulfan | 1 | 2014 | 18 | 0.110 |
Why?
|
| Mexican Americans | 1 | 2014 | 14 | 0.110 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2014 | 23 | 0.110 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 102 | 0.110 |
Why?
|
| Receptors, Cell Surface | 2 | 2006 | 429 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 1614 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 142 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 419 | 0.100 |
Why?
|
| Nutrition Surveys | 1 | 2014 | 142 | 0.100 |
Why?
|
| Fibronectins | 1 | 2013 | 43 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 111 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 730 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2015 | 469 | 0.100 |
Why?
|
| Morbidity | 2 | 2023 | 113 | 0.100 |
Why?
|
| Puerto Rico | 2 | 2023 | 134 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 574 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 57 | 0.100 |
Why?
|
| Longitudinal Studies | 5 | 2014 | 1254 | 0.090 |
Why?
|
| Aging | 1 | 2018 | 746 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2014 | 162 | 0.090 |
Why?
|
| Time Factors | 6 | 2021 | 3754 | 0.090 |
Why?
|
| Symptom Flare Up | 2 | 2022 | 13 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 349 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2015 | 93 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2023 | 180 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2020 | 498 | 0.080 |
Why?
|
| Bronchoscopy | 2 | 2009 | 87 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 834 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2011 | 203 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2011 | 332 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 713 | 0.070 |
Why?
|
| Boston | 2 | 2020 | 251 | 0.070 |
Why?
|
| Blood Gas Analysis | 1 | 2007 | 34 | 0.070 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 43 | 0.070 |
Why?
|
| Electrocardiography | 2 | 2011 | 554 | 0.070 |
Why?
|
| ROC Curve | 3 | 2016 | 281 | 0.070 |
Why?
|
| Hydrogels | 1 | 2009 | 115 | 0.070 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2007 | 1 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 377 | 0.070 |
Why?
|
| Leukotriene B4 | 1 | 2007 | 12 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2007 | 64 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2014 | 1293 | 0.070 |
Why?
|
| Serpins | 1 | 2006 | 18 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 213 | 0.060 |
Why?
|
| Mice | 6 | 2018 | 10816 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 934 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2020 | 682 | 0.060 |
Why?
|
| Genetic Linkage | 1 | 2005 | 96 | 0.060 |
Why?
|
| Social Class | 2 | 2019 | 133 | 0.060 |
Why?
|
| Linear Models | 1 | 2007 | 408 | 0.060 |
Why?
|
| Phenotype | 2 | 2021 | 1199 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 2179 | 0.060 |
Why?
|
| Oxidative Stress | 2 | 2017 | 297 | 0.050 |
Why?
|
| Animals | 7 | 2018 | 20610 | 0.050 |
Why?
|
| Rest | 2 | 2016 | 46 | 0.050 |
Why?
|
| Africa | 1 | 2023 | 27 | 0.050 |
Why?
|
| Sex Factors | 2 | 2021 | 978 | 0.050 |
Why?
|
| Exercise | 2 | 2020 | 939 | 0.050 |
Why?
|
| Respiratory Muscles | 1 | 2003 | 16 | 0.050 |
Why?
|
| Gene Expression | 1 | 2006 | 837 | 0.050 |
Why?
|
| Mucus | 1 | 2002 | 15 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2022 | 151 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 765 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2017 | 1004 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 1645 | 0.040 |
Why?
|
| Uncertainty | 1 | 2020 | 37 | 0.040 |
Why?
|
| Beijing | 1 | 2020 | 1 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2020 | 20 | 0.040 |
Why?
|
| England | 1 | 2020 | 29 | 0.040 |
Why?
|
| Massachusetts | 1 | 2006 | 2073 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 3387 | 0.040 |
Why?
|
| Cough | 1 | 2002 | 183 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 393 | 0.040 |
Why?
|
| Apoptosis | 2 | 2015 | 1073 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2020 | 69 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2015 | 5625 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 155 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 111 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 303 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 373 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 174 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1274 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 57 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 738 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 75 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 97 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4673 | 0.040 |
Why?
|
| Epigenomics | 1 | 2018 | 62 | 0.030 |
Why?
|
| Radiography | 2 | 2010 | 540 | 0.030 |
Why?
|
| Eosinophils | 1 | 2017 | 46 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 1001 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 119 | 0.030 |
Why?
|
| Health Surveys | 1 | 2018 | 313 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 8 | 0.030 |
Why?
|
| Serpin E2 | 2 | 2006 | 3 | 0.030 |
Why?
|
| Protease Nexins | 2 | 2006 | 3 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 123 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 510 | 0.030 |
Why?
|
| Lod Score | 2 | 2005 | 23 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 1092 | 0.030 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2015 | 1 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2015 | 8 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2015 | 8 | 0.030 |
Why?
|
| Fatigue | 2 | 2009 | 111 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2015 | 41 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 29 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 43 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 47 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 221 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 253 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 147 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 259 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1372 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 261 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 108 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 473 | 0.030 |
Why?
|
| Unrelated Donors | 1 | 2014 | 8 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2014 | 22 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 147 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 86 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 46 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 296 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 104 | 0.030 |
Why?
|
| Pulmonary Medicine | 1 | 2014 | 41 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 172 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 291 | 0.030 |
Why?
|
| Child | 1 | 2022 | 4520 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 308 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 862 | 0.020 |
Why?
|
| Florida | 1 | 2011 | 48 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 377 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1559 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 734 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 886 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 93 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2107 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 608 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1007 | 0.020 |
Why?
|
| Leukocytosis | 1 | 2009 | 13 | 0.020 |
Why?
|
| Fever | 1 | 2009 | 66 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1143 | 0.020 |
Why?
|
| Residual Volume | 1 | 2007 | 3 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 191 | 0.020 |
Why?
|
| Haplotypes | 1 | 2005 | 131 | 0.010 |
Why?
|
| Inspiratory Capacity | 1 | 2004 | 2 | 0.010 |
Why?
|
| Total Lung Capacity | 1 | 2004 | 13 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 2004 | 52 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 892 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 542 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 491 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2003 | 50 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2003 | 97 | 0.010 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2002 | 46 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2003 | 202 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 345 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1536 | 0.010 |
Why?
|